BostonSight

Categories

Health Care ServicesVisionNonprofit FoundationMedical PracticesManufacturingNonprofitNonprofit Health Agency

About Us

BostonSight® is a nonprofit eye care clinic and research center dedicated to restoring vision and improving quality of life. We strive to transform the understanding, treatment, and care of complex corneal disease within the global medical community and the public at large and empower practitioners to elevate the standard of care for patients. Founded in 1992, our center of excellence includes a medical institute, research center, state-of-the-art FDA-certified and ISO-compliant manufacturing lab, and patient and family support center.

BostonSight® PROSE is a medical treatment that uses highly customized, large-diameter devices to restore visual and physiological function in patients with ocular surface disease, corneal disease, injury, or damage. For many patients, our treatment is their only option to restore their vision and end the suffering from critical and devastating eye issues. PROSE is available at top-ranked academic medical centers and clinics around the world through the BostonSight Network.

BostonSight SCLERAL optimizes fitting efficiency and increases satisfaction for patients and practitioners alike. Practitioners can more quickly and effectively help their patients achieve optimal vision and comfort with our ready-to-fit scleral lens option. ?SCLERAL-IG is the newest innovation in BostonSight’s portfolio, using image topography to map the eye for a truly custom scleral lens fit. BostonSight envisions a world where no one suffers loss of sight from corneal irregularities or ocular surface disease.

Images

Gallery Image PD_on_finger2___BT_WM_L___20130111.jpg
Gallery Image Female_patient_inserts_PROSE_device.jpg
Gallery Image BostonSight_Icon_2020__RGB.png

Rep/Contact Info

Mr. Glen Bunnell
CFO
Michele Hart
Laurel Lucrezia
Chief Business Development Officer
Contact Us Button

HAVE A QUESTION?

We're here to help. Call (617)-244-5300 or use this form to reach us.

 


Sign up for our e-newsletter